• Skip to content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer

Trading With Cody

Long-term Revolution Investments and Real-time Trades from Cody Willard


  • Twitter

  • YouTube

  • iTunes Podcasts

  • SoundCloud
  • Trade Alerts
  • Latest Positions
  • All Archives
  • Chat Room
  • Books
  • About/FAQ/More Info
    • Testimonials
    • FAQ
    • Contact
    • Privacy Policy
    • Support
    • Money management services
    • Public Speaking
    • Cancellation Policy
    • Login

Our Covid-19 Vaccine Stock Is Flying. Here’s The Playbook.

May 19, 2020 by Cody Willard Leave a Comment

Our investment in a Covid-19 vaccine potential, Dynavax, is rocking this morning, up 40% in the pre-market near $7 per share and up nicely from the $4ish level where we started buying it. Recall that I’d bought a second tranche the other day when the stock was down on no news with the rest of the small cap stocks. The reason for the pop is this news, which the company filed last night with the SEC, bolded is mine:

‘In meetings with securities analysts and investors to be held on May 19, 2020 in connection with a vaccine investor day, Dynavax Technologies Corporation (the “Company”) intends to provide an update on its early-stage collaborations regarding the potential development of a vaccine for COVID-19 containing the Company’s proprietary toll-like receptor 9 agonist adjuvant CpG-1018 (“CpG-1018”), the adjuvant used in the Company’s HEPLISAV-B product. Accordingly, the Company is filing this Current Report on Form 8-K for the purpose of updating the disclosure contained in its prior filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 11, 2020. The update is that the Company expects that one or more of its collaboration partners will commence a Phase 1 clinical trial of a potential COVID-19 vaccine as soon as July 2020.‘  

So, that’s pretty much what we were looking for as the company partners with other companies that are developing potential vaccines for Covid-19.

In case you missed it, here’s what I said about DVAX in the video Q&A Chat on Friday, explaining how this company’s technology works and our reasons for owning a little further:

‘What I like about, one of the things I like about DVAX‘s, Dynavax’s approach here is that it’s not like it’s trying to develop the COVID vaccine entirely on its own. It’s partnering with 10, 12, maybe 20 different institutions of different sorts, whether for-profit or not-for-profit, that are developing and spending money trying to develop a vaccine.

But those vaccines need an adjuvant. An analogy that you can make here is that if you create the vaccine and administer it without the adjuvant, you might build enough supply for even 100 million people. But if you use the adjuvant, you could use the same dosage that you had built for 100 million people and actually get maybe 500 billion or a billion people, because the adjuvant allows you to use less of the actual vaccine to generate the body’s response that is required.

And this is just a play that gives us some broad exposure instead of just picking one vaccine play. It gives us maybe 10 or 12, if any of those work, and they might not. Then of course you still have the value of Dynavax’s adjuvant anyway, along with especially their hep B and other potential antiviral vaccine stuff that they’re developing.’

So now what? Well, as you might expect, I am going to trim a little bit here into this pop this morning, locking in some very nice gains in a stock we just started buying a few days ago. And I’ll be keeping a core position in this name as the company would have a lot of upside from here if any of their partners succeed in developing a vaccine.

Related posts:

How do I find a job in finance and other must-read articles (Updated)
Foxconn is one of the biggest contract m...
Weekly Q&A today at 2pm EST
The Voice Revolution Redux: Alexa says we'll talk to her 146 trillion times per year
Trade Alert: Betting against this glittery stuff
  • Twitter
  • YouTube
  • iTunes Podcasts
  • SoundCloud

Filed Under: Trading

Disclosure: At the time of publication, the firm in which Willard is a partner and/or Mr. Willard had positions in some of the stocks mentioned above although positions can change at any time and without notice.

Reader Interactions

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

Must Read Articles (Free)

How To Invest In Business Models From Outer Space
Everything You Need To Know About Cryptocurrencies

You are not currently logged in.








» Register
» Lost your Password?

Subscribe now. You can cancel at anytime.

Buy with Crypto

Footer

This does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or cryptocurrency or token any other product or service by Cody Willard or any other third party. Furthermore, nothing in this is intended to provide tax, legal, or investment advice and nothing in this should be construed as a recommendation to buy, sell, or hold any investment or security or cryptocurrency or token or to engage in any investment strategy or transaction. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your business advisor, attorney, or tax and accounting advisor regarding your specific business, legal or tax situation.

Copyright © 2023 · Magazine Pro on Genesis Framework · WordPress · Log in